



30 October 2023  
EMA/CHMP/591346/2022  
Committee for Medicinal Products for Human Use (CHMP)

## Metformin immediate-release film-coated tablets 500, 850 and 1000 mg product-specific bioequivalence guidance

<b>Draft agreed by Pharmacokinetics Working Party (PKWP) / Methodology Working Party (MWP)</b>	30 January 2023
<b>Adopted by CHMP for release for consultation</b>	30 March 2023
<b>Start of public consultation</b>	9 June 2023
<b>End of consultation (deadline for comments)</b>	30 September 2023
<b>Agreed by Methodology Working Party (MWP)</b>	9 October 2023
<b>Adopted by CHMP</b>	30 October 2023
<b>Date for coming into effect</b>	1 June 2024

<b>Keywords</b>	<b><i>Bioequivalence, generics, metformin</i></b>
-----------------	---



# Metformin immediate-release film-coated tablets 500, 850 and 1000 mg product-specific bioequivalence guidance

## Disclaimer:

*This guidance should not be understood as being legally enforceable and is without prejudice to the need to ensure that the data submitted in support of a marketing authorisation application complies with the appropriate scientific, regulatory and legal requirements.*

## Requirements for bioequivalence demonstration (PKWP)\*

<b>BCS Classification**</b>	<b>BCS Class:</b> <input type="checkbox"/> I <input checked="" type="checkbox"/> III <input type="checkbox"/> Neither of the two <b>Background:</b> Metformin is considered a high solubility compound with limited absorption.
<b>Bioequivalence study design</b> <i>in case a BCS biowaiver is not feasible or applied</i>	<b>single dose</b>
	<b>cross-over</b>
	<b>healthy volunteers</b>
	<input type="checkbox"/> <b>fasting</b> <input type="checkbox"/> <b>fed</b> <input type="checkbox"/> <b>both</b> <input checked="" type="checkbox"/> <b>either fasting or fed</b> The SmPC recommends intake in fed state to minimise the risk of gastrointestinal irritations. A fed study is, therefore, acceptable. However, a fasted study is also acceptable.
	<b>Strength:</b> 1000 mg <b>Background:</b> Highest strength recommended. However, it is also possible to use the lower strengths for a drug with linear pharmacokinetics and high solubility.

	According to the SmPC of the reference product, “ <i>metformin absorption is saturable and incomplete. It is assumed that the pharmacokinetics of metformin absorption is non-linear</i> ”. However, according to publicly available data the non-linearity of metformin pharmacokinetics in the dose range is not large enough to meet EMA requirements (i.e. difference in dose-adjusted AUC is not more than 25%) and pharmacokinetics can, therefore be regarded as linear.
	<b>Number of studies:</b> one single dose study.
<b>Analyte</b>	<input checked="" type="checkbox"/> <b>parent</b> <input type="checkbox"/> <b>metabolite</b> <input type="checkbox"/> <b>both</b>
	<input checked="" type="checkbox"/> <b>plasma/serum</b> <input type="checkbox"/> <b>blood</b> <input type="checkbox"/> <b>urine</b>
	<b>Enantioselective analytical method:</b> <input type="checkbox"/> <b>yes</b> <input checked="" type="checkbox"/> <b>no</b>
<b>Bioequivalence assessment</b>	<b>Main pharmacokinetic variables:</b> AUC <sub>0-t</sub> and C <sub>max</sub>
	<b>90% confidence interval:</b> 80.00–125.00%

\* As intra-subject variability of the reference product has not been reviewed to elaborate this product-specific bioequivalence guideline, it is not possible to recommend at this stage the use of a replicate design to demonstrate high intra-subject variability and widen the acceptance range of C<sub>max</sub>. If high intra-individual variability (CV<sub>intra</sub> > 30%) is expected, the applicants might follow respective guideline recommendations.

\*\* This tentative BCS classification of the drug substance serves to define whether in vivo studies seem to be mandatory (BCS class II and IV) or, on the contrary (BCS Class I and III), the Applicant may choose between two options: in vivo approach or in vitro approach based on a BCS biowaiver. In this latter case, the BCS classification of the drug substance should be confirmed by the Applicant at the time of submission based on available data (solubility experiments, literature, etc.). However, a BCS-based biowaiver might not be feasible due to product specific characteristics despite the drug substance being BCS class I or III (e.g. in vitro dissolution being less than 85% within 15 min (BCS class III) or 30 min (BCS class I) either for test or reference, or unacceptable differences in the excipient composition).